There are currently 86 active clinical trials seeking participants for Lymphoma research studies. The states with the highest number of trials for Lymphoma participants are Ohio, Illinois, California and New York.
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
NCT06860880
Recruiting
This health services study will assess a multidisciplinary intervention program directed at fatigue mitigation among patients diagnosed with indolent lymphomas. Specifically, 30 subjects with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and 10 subjects with Follicular Lymphoma (FL), marginal zone lymphoma (MZL), lymphoplasmacytic lymphoma (LPL), Waldenström's Macroglobulinemia, or Cutaneous T Cell Lymphoma (CTCL) will be included.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/25/2025
Locations: North Carolina Basnight Cancer Hospital, Chapel Hill, North Carolina
Conditions: Indolent Lymphomas, Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Lymphoplasmacytic Lymphoma, Waldenstrom Macroglobulinemia, Cutaneous T Cell Lymphoma
Register for Updates
Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy
NCT05237986
Recruiting
Background: CAR T-cell therapy is a promising new treatment for blood cancers. During treatment, a person s T-cells are genetically changed to kill cancer cells. Researchers want to learn more about the effects of potential problems that may be associated with this treatment. We are specifically interested in learning if and how this treatment may affect the brain or your thinking skills. Objective: To learn if CAR T-cell therapy can affect how children and adults think, process, and remember... Read More
Gender:
ALL
Ages:
5 years and above
Trial Updated:
06/25/2025
Locations: Children s Hospital of Los Angeles, Los Angeles, California +2 locations
Conditions: Lymphoma, Leukemia
Register for Updates
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
NCT03223610
Recruiting
Background: B-cell lymphoma is a cancer of white blood cells found in the lymph nodes. It affects the system that fights infections and disease. Researchers want to learn how certain drugs work together to treat B-cell lymphomas. The drugs are venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR). Objective: To study the safety of ViPOR for people with B-cell lymphoma. Eligibility: People ages 18 and older with B-cell lymphoma whose cancer has returned or not improved af... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/25/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Burkitt Lymphoma
Register for Updates
Registry of Older Patients With Cancer
NCT01137825
Recruiting
RATIONALE: Gathering information about older patients with cancer may help the study of cancer in the future. PURPOSE: This research study is gathering information from older patients with cancer into a registry.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
06/24/2025
Locations: Seby B. Jones Cancer Center, Boone, North Carolina +6 locations
Conditions: Chronic Myeloproliferative Disorders, Cognitive/Functional Effects, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unspecified Adult Solid Tumor, Protocol Specific
Register for Updates
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
NCT03314974
Recruiting
This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further radiation). followed by a post-transplant graft-versus-host disease (GVHD) prophylaxis regimen of post-transplant cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolate mofetil (MMF).
Gender:
ALL
Ages:
60 years and below
Trial Updated:
06/23/2025
Locations: Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota
Conditions: Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Lymphoma, Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myeloproliferative Neoplasms, Myelofibrosis, Myelodysplasia, Refractory Anemia, High Risk Anemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone B-Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia, Diffuse Large Cell Non Hodgkins Lymphoma, Lymphoblastic Lymphoma, Burkitt Lymphoma, High Grade Non-Hodgkin's Lymphoma, Adult, Multiple Myeloma, Juvenile Myelomonocytic Leukemia, Biphenotypic/Undifferentiated/Prolymphocytic Leukemias, MRD Positive Leukemia, Natural Killer Cell Malignancies, Acquired Bone Marrow Failure Syndromes
Register for Updates
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
NCT01441089
Recruiting
Background: - Some genes may be associated with a greater chance of side effects during cancer treatment. These genes may also make certain treatments less effective. Researchers want to collect blood or cheek swab samples from people having cancer treatment to study these genes. Objectives: - To obtain a blood or cheek swab sample to study genetic differences that may affect cancer treatment. Eligibility: - Individuals with cancer who are being treated at the National Cancer Institute. De... Read More
Gender:
ALL
Ages:
3 years and above
Trial Updated:
06/21/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Prostate Cancer, Breast Cancer, Lung Cancer, Ovarian Cancer, Lymphoma
Register for Updates
A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant
NCT05540340
Recruiting
The purpose of this study is to find out whether it is practical to use a newer way to calculate melphalan dose given (called population PK model) in BEAM chemotherapy before AHCT. Standard dose is fixed for everybody and is calculated using height and weight. The population PK model, tested in this study, uses information based on people who have previously received melphalan and aims to calculate an optimal dose separately for each person. Study researchers think that the dose calculated using... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/20/2025
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Hodgkin, Lymphoma, Non-Hodgkin
Register for Updates
Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation
NCT03856216
Recruiting
The goal of this phase II clinical study is to learn about the safety of inotuzumab ozogamicin when given with fludarabine, with or without bendamustine, melphalan, and rituximab before and after a stem cell transplant. Researchers also want to learn if inotuzumab ozogamicin when given after a stem cell transplant can help control leukemia and lymphoma. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a chemotherapy drug called ozogamicin. Inotuzumab attaches to CD22-... Read More
Gender:
ALL
Ages:
Between 12 years and 75 years
Trial Updated:
06/19/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Lymphocytic Neoplasm, Lymphoma
Register for Updates
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
NCT02332668
Recruiting
Researchers are looking for new ways to treat children with different types of melanoma (skin cancer), solid tumors, and lymphomas (blood cancers) that are any of these: * Advanced, which means cancer spread in the body or cannot be removed with surgery * Relapsed, which means cancer has come back after it had responded to previous treatment (responded means it stopped growing, gets smaller, or disappeared) * Refractory, which means cancer did not respond to previous treatment Pembrolizumab is... Read More
Gender:
ALL
Ages:
Between 6 months and 17 years
Trial Updated:
06/12/2025
Locations: Call for Information (Investigational Site 0019), Aurora, Colorado +15 locations
Conditions: Melanoma, Lymphoma, Solid Tumor, Classical Hodgkin Lymphoma, Microsatellite-instability-high Solid Tumor
Register for Updates
AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies.
NCT06137144
Recruiting
This study is designed to evaluate the safety, tolerability, PK and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in participants with haematologic malignancies.
Gender:
ALL
Ages:
15 years and above
Trial Updated:
06/11/2025
Locations: Research Site, Miami, Florida +19 locations
Conditions: Lymphoma, Non-Hodgkin, Hodgkin Lymphoma
Register for Updates
Study of CAR-T Therapy in Older Patients
NCT04300998
Recruiting
This study is being done to find out how older patients respond to CAR-T cell therapy and how the treatment affects their quality of life. This is a quality of life study and participating in the study does not involve receiving any treatment, other than the standard treatment for participants' disease.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
06/10/2025
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Lymphoma, Refractory B-Cell Lymphoma, Lymphoma, B-Cell, DLBCL NOS, High-grade B-cell Lymphoma, Multiple Myeloma
Register for Updates
A Study of Mosunetuzumab in People With Follicular Lymphoma
NCT05389293
Recruiting
The purpose of this study is to find out if mosunetuzumab is an effective treatment in people with follicular lymphoma that was recently diagnosed and have not yet received any treatments for their disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/10/2025
Locations: Georgetown University (Data Collection Only), Washington, District of Columbia +8 locations
Conditions: Follicular Lymphoma, Lymphoma
Register for Updates